Digestive and breast cancer patients managed during the first wave of COVID-19 pandemic: Short and middle term outcomes

Table 11 Characteristics of breast cancer and performed surgeries

All results presented as n (%) unless specified		Breast, n = 20
Postoperative TNM staging	0	3 (15.0)
	IA	10 (50.0)
	IIA	3 (15.0)
	IIIA	1 (5.0)
	IIIB	2 (10.0)
	IV	1 (5.0)
Histology	Invasive carcinoma	19 (95.0)
	Ductal carcinoma in situ (high grade)	1 (5.0)
	Estrogen receptor (+/-)	15/5
	Progesteron receptor	11/9
	Her-2 (+/-)	3/16
	Nottingham prognostic index (N=19). [Mean/SD/Range]	3.65/1.11/ 2 - 6.60
	Oncotype score (N=7). [Mean/SD/Range]	48.86/23.53/10 - 80
Menopausal status1	Post/Pre-menopausal	15 (75.0)/4 (20.0)
Neoadjuvant therapies	Long-course chemotherapy	3 (15.0)
Previous COVID		1 (5.0)
CRITCON level	1	2 (10.0)
	2	10 (50.0)
	3	8 (40.0)
Resection	R0	17 (85.0)
	R1	2 (10.0)
	R2	1 (5.0)

¹1 patient not valuable (man).

R0: No microscopic disease; R1: Microscopic disease; R2: Macroscopic disease at margin; TNM: Tumor-node-metastasis.